Myopericarditis complicated by pulmonary embolism in an immunocompetent patient with acute cytomegalovirus infection: a case report

BMC Research Notes

Pierre Abgueguen⁴  Valérie Delbos⁴  Frédéric Rouleau²  Nathalie Viot²  Loïc Biere²  Alexandra Ducancelle¹  Yves Marie Vandamme³ 

[1] Department of Bacteriology and Virology, Centre Hospitalier Universitaire d’Angers, 4 rue Larrey, 49933 Angers, Cedex 9, France;Department of Cardiology, Centre Hospitalier Universitaire d’Angers, 4 rue Larrey, 49933 Angers, Cedex 9, France;Department of Infectious and Tropical Diseases, CHU Angers, 4 rue Larrey, 49933 Angers, Cedex 9, France;Department of Infectious Diseases and Internal Medicine, Centre Hospitalier Universitaire d’Angers, 4 rue Larrey, 49933 Angers, Cedex 9, France

关键词: Thrombosis;    Pulmonary embolism;    Myopericarditis;    Immunocompetent patient;    Cytomegalovirus;   

Others  :  1134082
DOI  :  10.1186/1756-0500-7-193

 received in 2013-03-13, accepted in 2014-03-04,  发布年份 2014

【 摘 要 】

Background

Primary acute cytomegalovirus infection in immunocompetent patients is common worldwide. Infection is most often asymptomatic or occurs sub-clinically with a self-limited mononucleosis-like syndrome. More rarely, the infection may lead to severe organ complications with pneumonia, myocarditis, pericarditis, colitis and hemolytic anemia. Recent cases of cytomegalovirus-associated thrombosis have also been reported sporadically in the medical literature.

Case presentation

We report here a case of simultaneous myopericarditis and pulmonary embolism in a 30-year-old man with no medical history. The patient was not immunocompromised. We discuss the possible role of acute cytomegalovirus infection in the induction of vascular damage and review relevant cases in the literature.

Conclusion

Thrombosis in patients with acute cytomegalovirus infection may be more frequent than is generally thought. Physicians need to be aware of the possible association between acute cytomegalovirus and thrombosis in immunocompetent patients, especially in the presence of severe systemic infection, as our case illustrates.

【 授权许可】

   
2014 Vandamme et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bate SL, Dollard SC, Cannon MJ: Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis 2010, 50(11):1439-1447.
• [2]Boeckh M, Geballe AP: Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011, 121(5):1673-1680.
• [3]Hyde TB, Schmid DS, Cannon MJ: Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 2010, 20(5):311-326.
• [4]Wreghitt TG, Teare EL, Sule O, Devi R, Rice P: Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2003, 37(12):1603-1606.
• [5]Klemola E, Von Essen R, Henle G, Henle W: Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 1970, 121(6):608-614.
• [6]Kyto V, Vuorinen T, Saukko P, Lautenschlager I, Lignitz E, Saraste A, Voipio-Pulkki LM: Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. Clin Infect Dis 2005, 40(5):683-688.
• [7]Chanarin I, Walford DM: Thrombocytopenic purpura in cytomegalovirus mononucleosis. Lancet 1973, 2(7823):238-239.
• [8]Stewart MW, Bolling JP, Mendez JC: Cytomegalovirus retinitis in an immunocompetent patient. Arch Ophthalmol 2005, 123(4):572-574.
• [9]Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME: Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008, 5:47. BioMed Central Full Text
• [10]Tajiri H, Kozaiwa K, Tanaka-Taya K, Tada K, Takeshima T, Yamanishi K, Okada S: Cytomegalovirus hepatitis confirmed by in situ hybridization in 3 immunocompetent infants. Scand J Infect Dis 2001, 33(10):790-793.
• [11]Schmitz H, Enders G: Cytomegalovirus as a frequent cause of Guillain-Barre syndrome. J Med Virol 1977, 1(1):21-27.
• [12]Eddleston M, Peacock S, Juniper M, Warrell DA: Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 1997, 24(1):52-56.
• [13]Abgueguen P, Delbos V, Chennebault JM, Payan C, Pichard E: Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients: report of 2 cases and literature review. Clin Infect Dis 2003, 36(11):E134-E139.
• [14]Justo D, Finn T, Atzmony L, Guy N, Steinvil A: Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med 2011, 22(2):195-199.
• [15]Abgueguen P, Delbos V, Ducancelle A, Jomaa S, Fanello S, Pichard E: Venous thrombosis in immunocompetent patients with acute cytomegalovirus infection: a complication that may be underestimated. Clin Microbiol Infect 2010, 16(7):851-854.
• [16]Rasanen V, Saikku P: [Cytomegalovirus hepatitis and pericarditis]. Duodecim 1968, 84(4):270-273.
• [17]Sterner G, Agell BO, Wahren B, Espmark A: Acquired cytomegalovirus infection in older children and adults. A clinical study of hospitalized patients. Scand J Infect Dis 1970, 2(2):95-103.
• [18]Wilson RS, Morris TH, Rees JR: Cytomegalovirus myocarditis. Br Heart J 1972, 34(8):865-868.
• [19]Vanstechelman F, Vandekerckhove H: Cytomegalovirus myocarditis in an immunocompetent patient. Acta Cardiol 2012, 67(2):257-260.
• [20]Baumgratz JF, Vila JH, Silva JP, Fonseca L, Rodrigues EA, Knobel E: Cardiogenic shock due to cytomegalovirus myocarditis: successful clinical treatment. Rev Bras Cir Cardiovasc 2010, 25(2):149-153.
• [21]Roubille C, Brunel AS, Gahide G, Vernhet Kovacsik H, Le Quellec A: Cytomegalovirus (CMV) and acute myocarditis in an immunocompetent patient. Intern Med 2010, 49(2):131-133.
• [22]Fernández-Ruiz M, Muñoz-Codoceo C, López-Medrano F, Faré-García R, Carbonell-Porras A, Garfia-Castillo C, Muñoz-Gómez R, Aguado-García JM: Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med 2008, 47(22):1963-1966.
• [23]Zubiaurre L, Zapata E, Bujanda L, Castillo M, Oyarzabal I, Gutiérrez-Stampa MA, Cosme A: Cytomegalovirus hepatitis and myopericarditis. World J Gastroenterol 2007, 13(4):647-648.
• [24]Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH: [Guidelines on the diagnosis and management of pericardial diseases. Executive summary]. Rev Esp Cardiol 2004, 57(11):1090-1114.
• [25]Hufnagel G, Pankuweit S, Richter A, Schonian U, Maisch B: The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 2000, 25(3):279-285.
• [26]Bonnet F, Morlat P, Neau D, Viallard JF, Ragnaud JM, Dupon M, Legendre P, Imbert Y, Lifermann F, Le Bras M, Beylot J, Longy-Boursier M: [Hematologic and immunologic manifestations of primary cytomegalovirus infections in non-immunocompromised hospitalized adults]. Rev Med Interne 2000, 21(7):586-594.
• [27]Nitsche A, Oswald O, Steuer N, Schetelig J, Radonic A, Thulke S, Siegert W: Quantitative real-time PCR compared with pp 65 antigen detection for cytomegalovirus (CMV) in 1122 blood specimens from 77 patients after allogeneic stem cell transplantation: which test better predicts CMV disease development? Clin Chem 2003, 49(10):1683-1685.
• [28]Leruez-Ville M, Ouachee M, Delarue R, Sauget AS, Blanche S, Buzyn A, Rouzioux C: Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol 2003, 41(5):2040-2046.
• [29]Sullivan PS, Dworkin MS, Jones JL, Hooper WC: Epidemiology of thrombosis in HIV-infected individuals. The adult/adolescent spectrum of HIV disease project. AIDS 2000, 14(3):321-324.
• [30]Jenkins RE, Peters BS, Pinching AJ: Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS 1991, 5(12):1540-1542.
• [31]Oh CK, Pelletier SJ, Sawyer RG, Dacus AR, McCullough CS, Pruett TL, Sanfey HA: Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 2001, 71(6):767-772.
• [32]Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE: Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996, 335(9):624-630.
• [33]Neumann FJ, Kastrati A, Miethke T, Pogatsa-Murray G, Seyfarth M, Schomig A: Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. Circulation 2000, 101(1):11-13.
• [34]Atzmony L, Halutz O, Avidor B, Finn T, Zimmerman O, Steinvil A, Zeltser D, Giladi M, Justo D: Incidence of cytomegalovirus-associated thrombosis and its risk factors: a case–control study. Thromb Res 2010, 126(6):e439-e443.
• [35]Schimanski SLB, Luxembourg B, Rochon J, Seifried E, Lindhoff-Last E, Schambeck CM: Cytomegalovirus infection is associated with venous thromboembolism - a case control study. J Thromb Haemost 2009, 7(Suppl 2):PP-MO-295.
• [36]Tichelaar VY, Sprenger HG, Makelburg AB, Niesters BG, Kluin-Nelemans HC, Lijfering WM: Active cytomegalovirus infection in patients with acute venous thrombosis: a case–control study. Am J Hematol 2011, 86(6):510-512.
• [37]Squizzato A, Gerdes VE, Buller HR: Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005, 93(3):403-410.
• [38]Delbos V, Abgueguen P, Chennebault JM, Fanello S, Pichard E: Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect 2007, 54(1):e47-e50.
• [39]Sutherland MR, Raynor CM, Leenknegt H, Wright JF, Pryzdial EL: Coagulation initiated on herpesviruses. Proc Natl Acad Sci U S A 1997, 94(25):13510-13514.
• [40]Bruggeman CA, Debie WH, Muller AD, Schutte B, van Dam-Mieras MC: Cytomegalovirus alters the von Willebrand factor content in human endothelial cells. Thromb Haemost 1988, 59(2):264-268.
• [41]The TH, Kas-Deelen AM, de Maar EF, Driessen C, Harmsen MC, van Son WJ: Cellular and humoral parameters for vascular damage in blood during cytomegalovirus infections. Transplant Proc 2001, 33(1–2):1813.
• [42]Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE: Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994, 265(5170):391-394.
• [43]Tanaka K, Zou JP, Takeda K, Ferrans VJ, Sandford GR, Johnson TM, Finkel T, Epstein SE: Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation 1999, 99(13):1656-1659.
• [44]Zhou YF, Yu ZX, Wanishsawad C, Shou M, Epstein SE: The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem Biophys Res Commun 1999, 256(3):608-613.
• [45]Zhou YF, Shou M, Guetta E, Guzman R, Unger EF, Yu ZX, Zhang J, Finkel T, Epstein SE: Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999, 100(14):1569-1575.
• [46]Visseren FL, Verkerk MS, Bouter KP, Diepersloot RJ, Erkelens DW: Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus. J Lab Clin Med 1999, 134(6):623-630.
• [47]Mach F, Schonbeck U, Libby P: CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998, 137(Suppl):S89-S95.
• [48]Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 2001, 89(12):1092-1103.